

References

I-212

1. Morrison R, Fedgchin m, Singh J, et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: A randomized, double-blind, placebo-controlled study. *Psychopharmacology*. 2018;235:1107-1119.
2. Daly E, Singh J, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment resistant depression: A randomized clinical trial. *JAMA Psychiatry*. 2018;75(2):139-148.
3. Spravato™ (esketamine) nasal spray [package insert]. Titusville, NJ. Janssen Phamaceuticals, Inc. 07/2020.
4. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
5. Canuso C, Singh J, Fedgchin M et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*. 2018.;175:620-630.
6. Targum S, Daly E, Fedgchin M, Cooper K, & Singh J. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. *J Psych Res*. 2019;111:68-73.
7. Hayes, Inc. Hayes Medical Technology Directory Report. Esketamine (Spravato) for Treatment Resistant Major Depressive Disorder Lansdale, PA: Hayes, Inc.; November 2019. Accessed May 7, 2020.
8. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. *JAMA Psychiatry*. 2019;76(9):893-903.
9. Wajs E, Aluisio L, Holder R, et.al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a Phase 3, open-label study (SUSTAIN-2). *J Clin Psychiatry*. 2020. 28;81(3)

10. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Esketamine.
11. Micromedex DrugDex Compendium®. 2024. Esketamine.
12. Kryst J, Kawalec P, Pilc A. et.al. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. *Expert Opinion on Pharmacotherapy*, 2020;21(1):9-20.
13. Fu D J, Ionescu D, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). *J Clin Psychiatry*. 2020;81(3):19m13191.
14. Esketamine In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated November 4, 2019.